Add to ORKGBackground: The long-term outcome for patients with ag-gressive non-Hodgkin’s lymphoma (NHL) is poor. Conse-quently, the European Organization for Research and Treat-ment of Cancer Lymphoma Group designed a prospective randomized trial to investigate whether high-dose chemo-therapy plus autologous bone marrow transplantation (ABMT) after standard combination chemotherapy im-proves long-term survival. Methods: Patients aged 15–65 years with aggressive NHL received three cycles of CHVmP/BV polychemotherapy (i.e., a combination of cyclophosphamide, doxorubicin, teniposide, and prednisone, with bleomycin and vincristine added at mid-cycle). After these three cycles, pa-tients with a complete or partial remission and at that time no lymphoma inv...
Purpose: To update the randomized study that compared consolidative sequential treatment (ifosfamide...
Purpose Timing, appropriate amount, and composition of treatment before high-dose therapy and autolo...
Background: Influenced by successful results treating inter-mediate- and high-grade non-Hodgkin&apos...
Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor....
Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor....
Long-term follow-up of numerous single-institution and na-tional cooperative group clinical trials h...
Background: Randomized controlled trials (RCTs) reported conflicting results on the impact of high-d...
Background: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those ...
Background: Randomized controlled trials (RCTs) reported conflicting results on the impact of high-d...
Background. Randomised controlled trials (RCTs) reported conflicting results on the impact of high-d...
Purpose: To evaluate the role of early intensification with high-dose therapy (HDT) and autologous s...
Single high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC) support impr...
PURPOSE: To evaluate, in a prospective multicentric study, the efficacy of a conventional salvage c...
PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autol...
Background: There is not univocal concordance for using high-dose sequential therapy (HDS) as first-...
Purpose: To update the randomized study that compared consolidative sequential treatment (ifosfamide...
Purpose Timing, appropriate amount, and composition of treatment before high-dose therapy and autolo...
Background: Influenced by successful results treating inter-mediate- and high-grade non-Hodgkin&apos...
Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor....
Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor....
Long-term follow-up of numerous single-institution and na-tional cooperative group clinical trials h...
Background: Randomized controlled trials (RCTs) reported conflicting results on the impact of high-d...
Background: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those ...
Background: Randomized controlled trials (RCTs) reported conflicting results on the impact of high-d...
Background. Randomised controlled trials (RCTs) reported conflicting results on the impact of high-d...
Purpose: To evaluate the role of early intensification with high-dose therapy (HDT) and autologous s...
Single high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC) support impr...
PURPOSE: To evaluate, in a prospective multicentric study, the efficacy of a conventional salvage c...
PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autol...
Background: There is not univocal concordance for using high-dose sequential therapy (HDS) as first-...
Purpose: To update the randomized study that compared consolidative sequential treatment (ifosfamide...
Purpose Timing, appropriate amount, and composition of treatment before high-dose therapy and autolo...
Background: Influenced by successful results treating inter-mediate- and high-grade non-Hodgkin&apos...